Thao P. Dang

1.7k citations

21 papers · 1.4k indexed · h-index 17

Molecular Biology
Oncology top 5%
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 10%
Immunology

Co-authors: David P. Carbone Adriana González Nobuhiro Haruki Keiko Kawaguchi Sandra J. Olson Jun Konishi Pierre P. Massion Yu Shyr
Topics: Developmental Biology and Gene Regulation (7 papers)Cancer Immunotherapy and Biomarkers (6 papers)Lung Cancer Treatments and Mutations (6 papers)
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology Blood Cancer Research
Partner nations: United States Spain Japan

In The Last Decade

Thao P. Dang

21 papers receiving 1.4k citations

Peers

Countries citing papers authored by Thao P. Dang

Since Specialization

Citations

This map shows the geographic impact of Thao P. Dang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thao P. Dang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thao P. Dang more than expected).

Fields of papers citing papers by Thao P. Dang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thao P. Dang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thao P. Dang. The network helps show where Thao P. Dang may publish in the future.

Co-authorship network of co-authors of Thao P. Dang

This figure shows the co-authorship network connecting the top 25 collaborators of Thao P. Dang. A scholar is included among the top collaborators of Thao P. Dang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thao P. Dang. Thao P. Dang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC 2023 ·International Journal of Cancer ·Shengxiang Ren,Jifeng Feng,Shenglin Ma,Huajun Chen,Zhiyong Ma,Cheng Huang,Li Zhang,Jianxing He,Changli Wang,Jianying Zhou,Pongwut Danchaivijitr,Chin‐Chou Wang,Ihor Vynnychenko,Kai Wang,Francisco J. Orlandi,Virote Sriuranpong,(unknown),Jun Ge,Thao P. Dang,Caicun Zhou	12
2	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study 2020 ·International Journal of Cancer ·Yi‐Long Wu,Li Zhang,Yun Fan,Jianying Zhou,Li Zhang,Qing Zhou,Wei Li,Chengping Hu,Gongyan Chen,Xin Zhang,Caicun Zhou,Thao P. Dang,(unknown),Debra Kush,Yu Zhou,Ben Li,Tony Mok	77
3	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). 2018 ·Journal of Clinical Oncology ·Peter Schmid,Javier Cortés,Jonas Bergh,Lajos Pusztai,Carsten Denkert,Sunil Verma,Heather L. McArthur,Sherko Kümmel,Yu Ding,Vassiliki Karantza,Thao P. Dang,Rebecca Dent	27
4	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. 2017 ·Journal of Clinical Oncology ·Peter Schmid,Yeon Hee Park,Eva Muñoz‐Couselo,Sung‐Bae Kim,Joohyuk Sohn,Seock‐Ah Im,Esther Holgado,Yang Wang,Thao P. Dang,Gursel Aktan,Javier Cortés	68
5	KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC). 2016 ·Journal of Clinical Oncology ·Eric P. Winer,Thao P. Dang,Vassiliki Karantza,Shu‐Chih Su	18
6	Manic fringe inhibits tumor growth by suppressing Notch3 degradation in lung cancer. 2013 ·PubMed ·(unknown),(unknown),Thao P. Dang	15
7	Notch, Apoptosis and Cancer 2012 ·Advances in experimental medicine and biology ·Thao P. Dang	71
8	Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation 2011 ·Molecular Cancer ·Kevin D. Vo,(unknown),Kay Washington,Adriana González,Jordan Berlin,Thao P. Dang	53
9	Targeting Specific Regions of the Notch3 Ligand-Binding Domain Induces Apoptosis and Inhibits Tumor Growth in Lung Cancer 2010 ·Cancer Research ·Luping Lin,Ray Mernaugh,(unknown),David Blum,David P. Carbone,Thao P. Dang	55
10	Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen 2009 ·Journal of Thoracic Oncology ·(unknown),Heidi Chen,Shuo Chen,Roy S. Herbst,Anne S. Tsao,Hai T. Tran,Alan Sandler,Dean Billheimer,Yu Shyr,Ju-Whei Lee,Pierre P. Massion,Julie R. Brahmer,Joan H. Schiller,David P. Carbone,Thao P. Dang	23
11	VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab 2009 ·Lung Cancer ·David P. Carbone,(unknown),Dean Billheimer,Heidi Chen,Alan Sandler,Heinrich Röder,(unknown),Maxim Tsypin,Roy S. Herbst,Anne S. Tsao,Hai T. Tran,Thao P. Dang	45
12	Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer 2007 ·Clinical Cancer Research ·Roy S. Herbst,Angela M. Davies,Ronald B. Natale,Thao P. Dang,Joan H. Schiller,Linda L. Garland,Vincent A. Miller,David S. Mendelson,Annick D. Van den Abbeele,Yulia Melenevsky,D.J. de Vries,David A. Eberhard,Benjamin Lyons,Stuart Lutzker,Bruce E. Johnson	79
13	γ-Secretase Inhibitor Prevents Notch3 Activation and Reduces Proliferation in Human Lung Cancers 2007 ·Cancer Research ·Jun Konishi,Keiko Kawaguchi,(unknown),Nobuhiro Haruki,Adriana González,David P. Carbone,Thao P. Dang	220
14	Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel 2005 ·Clinical Cancer Research ·Ildiko Csiki,Jason D. Morrow,Alan Sandler,Yu Shyr,John Oates,(unknown),Thao P. Dang,David P. Carbone,David H. Johnson	91
15	Dominant-Negative Notch3 Receptor Inhibits Mitogen-Activated Protein Kinase Pathway and the Growth of Human Lung Cancers 2005 ·Cancer Research ·Nobuhiro Haruki,Keiko Kawaguchi,(unknown),Pierre P. Massion,Sandra J. Olson,Adriana González,David P. Carbone,Thao P. Dang	133
16	Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain 2004 ·Blood ·Dmitri V. Kravtsov,Wenman Wu,Joost C.M. Meijers,Mao-fu Sun,Morey A. Blinder,Thao P. Dang,Hongli Wang,David Gailani	71
17	Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice 2003 ·Oncogene ·Thao P. Dang,(unknown),Adriana González,Sandra J. Olson,David P. Carbone	88
18	A training-testing approach to the molecular classification of resected non-small cell lung cancer. 2003 ·PubMed ·Noboru Yamagata,Yu Shyr,Kiyoshi Yanagisawa,Mary E. Edgerton,Thao P. Dang,Adriana González,Sorena Nadaf,(unknown),John R. Roberts,Jonathan C. Nesbitt,Roy A. Jensen,Shawn Levy,Jason H. Moore,John D. Minna,David P. Carbone	94
19	Positive Correlations Between Cerebral Protein Synthesis Rates and Deep Sleep in Macaca mulatta 1997 ·European Journal of Neuroscience ·Hajime Nakanishi,Yun Sun,Richard Nakamura,Kentaro Mori,Masanori Ito,S. Suda,Hiroki Namba,(unknown),Thao P. Dang,Wallace B. Mendelson,Mortimer Mishkin,Charles Kennedy,J. Christian Gillin,Carolyn Beebe Smith,Louis Sokoloff	120
20	Chromosomal abnormalities associated with infertility. 1980 ·PubMed ·(unknown),Thao P. Dang,Karen A. Ferguson,Samuel Ward,Roger L. Ladda	11

About Thao P. Dang

Thao P. Dang is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 21 papers that have together received 1.4k indexed citations. Recurring topics across this work include Developmental Biology and Gene Regulation (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Treatments and Mutations (6 papers). The work is most often cited by research in Oncology (561 citations), Cancer Research (243 citations) and Pulmonary and Respiratory Medicine (364 citations). Thao P. Dang has collaborated with scholars based in United States, Spain and Japan. Frequent co-authors include David P. Carbone, Adriana González, Nobuhiro Haruki, Keiko Kawaguchi, Sandra J. Olson, Jun Konishi, Pierre P. Massion, Yu Shyr, Alan Sandler and Roy S. Herbst. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact